Lonza has recently adjusted its forecast, showcasing improved performance under a new strategic approach that is yielding positive outcomes. This shift in strategy is positioning the company for growth and success in the competitive biotechnology and pharmaceutical industries. By prioritizing operational efficiency and revenue maximization, Lonza is making significant progress towards achieving its business objectives and strengthening its market position.
Swiss contract development and manufacturing group Lonza (SWX: LONN) reported a remarkable 19% increase in revenue at constant currencies to 3.6 billion Swiss francs ($4.5 billion) for the first half of 2025. This growth was primarily fueled by robust demand across its core CDMO operations, indicating the effectiveness of the new strategic direction. Core earnings per share also saw a notable uptick, rising by 7% to 7.52 francs ($9.01).
Furthermore, Lonza’s net profit surged by 29% year-on-year to 426 million francs ($511 million), with basic earnings per share experiencing a substantial 32% increase. The company’s core CDMO business contributed significantly to its total revenue, reaching 3.1 billion francs ($3.9 billion) and marking a substantial 23% growth compared to the same period in 2024.
The impressive performance was further bolstered by the strong utilization of mammalian drug substance production, particularly at Lonza’s Vacaville, California, facility. Acquired from Roche (ROG: SIX) for $1.2 billion in 2024, this large-scale site exceeded expectations and is projected to generate approximately half a billion francs ($600 million) in sales this year.
To delve deeper into this compelling success story and stay updated on the latest developments in the pharmaceutical and biotechnology sectors, readers can access exclusive features, interviews, round-ups, and expert commentary by registering on thepharmaletter.com. This platform offers valuable insights from industry leaders, making it a must-visit resource for staying informed about the dynamic landscape of biotech and pharma. Sign up now for email updates and join the community of professionals dedicated to exploring the forefront of CDMO revenue forecast news.
Tags: biotechnology
Read more from thepharmaletter.com